- Ongoing, recruitingTherapeutic use (Phase IV)
Pharmacodynamic Outcomes in patients with coronary artery disease undergoing Percutaneous coronary intervention treated with an individualized treatment STRATEGY (POPular STRATEGY PD)
This study looks at different blood-thinning medicines for people who have had a heart procedure called a stent. Researchers want to see which medicine works best to prevent blood clots while also checking for any bleeding, to help doctors choose the right treatment for each patient.
For: Stable coronary artery disease · Chronic coronary syndromeNetherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE I/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEBENDAZOLE IN COMBINATION WITH LOW-DOSE ARA-C IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (MAIL)
This study is looking at a new way to treat acute myeloid leukaemia (AML) in older patients where other treatments haven't worked or stopped working. It combines two medicines, mebendazole and Ara-C, to see if they are safe and effective together.
For: relapsed/refractory acute myeloid leukemiaGermany - AuthorisedTherapeutic confirmatory (Phase III)
MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study. An international, multicentre, randomised-controlled, two-arm, assessor-blinded trial.
This study, called MOSES, is looking at how best to prevent another stroke in people who have recently had one. It's testing if a specific blood test, together with different blood-thinning medicines, can help doctors choose the best treatment to stop future strokes.
For: Acute ischemic strokeGreece · Spain